Why the study?
Antithrombotic therapy in patients with nonvalvular AF undergoing PCI is clinically challenging, with real-world strategies often remaining inconsistent.
What are the real-world antithrombotic management strategies in Chinese patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention?
Population
1306 patients with nonvalvular AF undergoing PCI across 36 centers in Shanghai
Comparison
Antithrombotic therapy strategies including DAPT and OACs
Design
Multicenter cross-sectional study
Key result
In Chinese patients with NVAF undergoing PCI, oral anticoagulants were underutilized, with OAC recipients having higher rates of persistent AF than non-recipients (53.2% vs 33.9%, P<0.001).
Authors
Loading...
Highlights OAC underuse in Chinese NVAF-PCI patients; leaves open whether interventions can improve guideline adherence.
Cross-Sectional (n=1,306)
Yes
What are the real-world antithrombotic management strategies in Chinese patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention?
Absolute Event Rate: 53.2% vs 33.9%
p-value: p=<0.001
There is a substantial gap between guideline recommendations and real-world practice in Chinese AF patients undergoing PCI, characterized by an overreliance on DAPT and underutilization of oral anticoagulants.
Yu et al. (2026) conducted a cross-sectional in Nonvalvular atrial fibrillation (NVAF) undergoing percutaneous coronary intervention (PCI) (n=1,306). Oral anticoagulants (OACs) vs. No OAC therapy was evaluated on Persistent atrial fibrillation (p=<0.001). In Chinese patients with NVAF undergoing PCI, oral anticoagulants were underutilized, with OAC recipients having higher rates of persistent AF than non-recipients (53.2% vs 33.9%, P<0.001).